Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) on Monday announced positive interim Phase 3 results from the SUCCESSOR-2 study evaluating oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in patients with relapsed or refractory multiple myeloma.

The combination demonstrated statistically significant and clinically meaningful improvement in progression-free survival compared with carfilzomib and dexamethasone alone (Kd).

Safety findings were consistent with the known profile of mezigdomide and the combination regimen.

SUCCESSOR-2 is a seamless Phase 2/3, multicentre, randomised, open-label study designed to assess the efficacy and safety of MeziKd versus Kd. Patients in the study will continue to be monitored for survival and safety outcomes. Data from the trial will be presented at a future medical meeting and shared with health authorities, Bristol Myers Squibb said.

This marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 result for Bristol Myers Squibb's CELMoD programme.